^
Association details:
| Biomarker: | PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
Excerpt:
Molecular profiling of the tumor was remarkable for PPFIBP1-ALK translocation...However, she experienced progression on alectinib after 5 months and was placed back on FOLFIRINOX. Subsequent cell-free plasma...showed newly acquired ALK mutations G1202R and V1180L in addition to the PPFIBP1-ALK translocation. The patient experienced progression quickly on FOLFIRINOX and was transitioned to lorlatinib. The patient’s disease has been stable on lorlatinib on 2-month follow-up imaging, and she continues to be treated with lorlatinib.
DOI:
10.1200/PO.19.00365
